CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 68 enrolled
Drug / intervention
d-cycloserine +1 moredrug
Likely dose
d-cycloserine 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00842309
NCT00842309Early Ph 1Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder

Massachusetts General Hospital·interventional·Posted Feb 12, 2009·Updated Jun 18, 2019

In Brief

A Early Phase 1 clinical trial evaluating d-cycloserine and Placebo for Body Dysmorphic Disorder. Completed, enrolled 68 participants across 1 site.

Detailed Summary

The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBody Dysmorphic Disorder
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2009
Enrollment StartNov 1, 2008
Primary CompletionDec 1, 2017
Study CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 17.4 years ago

Interventions

d-cycloserinedrug

100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.

Placebodrug

Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.